The growing development effort into evaluating RNA as a target for novel therapeutics could lead to a novel type of therapy to treat heart failure, according to the clinical-stage German biotech, Cardior Pharmaceuticals GmbH.
Cardior has started a Phase Ib clinical study with its lead compound, CDR132L, an antisense oligonucleotide that inhibits a non-coding...